Nano-X Imaging Ltd. (NNOX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: slight revenue growth and strategic market expansion are positive, but increased losses and vague management responses in the Q&A section are concerning. The company's focus on AI and regulatory achievements offer long-term potential, but short-term financial metrics and execution risks temper optimism. With no clear guidance improvement, the stock is likely to remain stable in the near term.
Key Financial Performance
GAAP net loss $14.7 million for Q2 2025, compared to $13.6 million in Q2 2024, an increase due to a $0.4 million rise in gross loss and $1.0 million increase in finance expenses, partially offset by a $0.4 million decrease in operating expenses.
Revenue $3.0 million for Q2 2025, compared to $2.7 million in Q2 2024, a year-over-year increase attributed to customer retention, increased rates, and higher service volumes.
Gross loss (GAAP) $3.2 million for Q2 2025, compared to $2.9 million in Q2 2024, reflecting a higher gross loss margin of 21% versus 9% in the prior year.
Teleradiology services revenue $2.7 million for Q2 2025, compared to $2.5 million in Q2 2024, with gross profit increasing to $0.5 million from $0.4 million due to customer retention, increased rates, and higher service volumes.
AI solutions revenue $0.1 million for Q2 2025, unchanged from Q2 2024, with a gross loss of $2.0 million in both periods.
Research and development expenses $4.8 million for Q2 2025, unchanged from Q2 2024, with decreases in share-based compensation and development activity expenses offset by increases in salaries and reduced grants.
Sales and marketing expenses $1.2 million for Q2 2025, up from $0.8 million in Q2 2024, driven by higher salaries and marketing activities related to U.S. commercialization.
General and administrative expenses $5.1 million for Q2 2025, down from $5.9 million in Q2 2024, due to lower share-based compensation, legal expenses, and D&O insurance costs, partially offset by higher salaries.
Non-GAAP net loss $10.9 million for Q2 2025, compared to $8.4 million in Q2 2024, an increase driven by higher gross loss, operating expenses, and financial expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nanox.ARC systems: Steady progress towards the goal of 100 installations by the end of 2025. Systems are being installed in the U.S. and Europe, including Romania and Greece, following the CE mark designation.
Mobile imaging solution: Development of a mobile imaging solution integrating Nanox.ARC into a commercial vehicle to expand access to diagnostic imaging.
Nanox.AI collaborations: Collaborations with AI providers to integrate liver, bone, and lung products into advanced visualization software and platforms like deepcOS.
U.S. market expansion: Increased installations in the U.S., including partnerships with imaging chains and universities like Keiser University.
European market entry: Accelerated efforts in Europe with the CE mark designation, partnerships in Romania and Greece, and plans for expansion in other EU countries.
India and Latin America: Pilot projects in India and efforts to secure import licenses in Mexico.
Manufacturing and supply chain: Entered a multiyear agreement with Fabrinet for scalable production of Nanox.ARC X systems, ensuring cost-effective and reliable manufacturing.
Sales pipeline: Substantial growth in the sales pipeline due to investments in sales development initiatives.
Clinical education and partnerships: Collaborations with academic institutions like Duke University and Keiser University for clinical studies and training programs.
Key opinion leaders: Strengthened Medical Advisory Board with experts to amplify clinical credibility and support commercialization.
AI-driven health solutions: Partnerships with AI providers for population health studies and integration into clinical workflows.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company is awaiting FDA clearance for its TAP2D software module, which is critical for enhancing diagnostic confidence. Delays or failure in obtaining this clearance could impact product adoption and market expansion.
Supply Chain Challenges: The company is dependent on suppliers like Varex for glass tubes and Fabrinet for manufacturing. Any disruptions in these supply chains could delay production and deployment of the Nanox.ARC systems.
Financial Losses: The company reported a GAAP net loss of $14.7 million for Q2 2025, an increase from $13.6 million in Q2 2024. This ongoing financial loss could strain resources and impact operational capabilities.
Market Penetration Risks: Despite progress, the company faces challenges in scaling its commercial footprint, particularly in new markets like Europe and Latin America, where regulatory and logistical hurdles exist.
Technological Adoption: The company is working to change healthcare provider habits and integrate new technology like the Nanox.ARC system. Resistance to change or slow adoption could hinder growth.
Economic Uncertainties: The company’s financial performance is sensitive to broader economic conditions, which could impact customer spending and investment in new technologies.
Operational Execution: The company is pursuing a multifaceted growth strategy, including AI integration and mobile imaging solutions. Any missteps in execution could dilute focus and resources, impacting overall performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Revenues are expected to grow in the second half of 2025.
Nanox.ARC System Installations: The company is on track to meet its target of 100 Nanox.ARC systems installed or deployed by the end of 2025.
Geographic Expansion: The company is expanding its commercial footprint in the U.S. and internationally, including Europe (e.g., Romania and Greece) and Latin America (e.g., Mexico).
Mobile Imaging Solution: Nanox is developing a mobile imaging solution integrating the Nanox.ARC system into a commercial vehicle to expand access to diagnostic imaging.
Nanox.AI Collaborations: Nanox.AI is collaborating with multiple partners to integrate its AI solutions into various platforms, including liver, bone, and lung imaging products. These collaborations aim to expand the customer base and enhance clinical outcomes.
Regulatory Developments: The company plans to submit the TAP2D software module to the FDA for clearance, which will enhance diagnostic confidence for radiologists.
Manufacturing and Supply Chain: Nanox has entered into a multiyear Volume Supply Agreement with Fabrinet to support scalable production of the Nanox.ARC X system, ensuring cost-effective and reliable manufacturing.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many systems were operating during the quarter that resulted in $221,000 in imaging-related revenue?
A:More than 20 systems were operating and scanning patients during the quarter.
Q:Are you expecting any of the 100 leads to be capital sales, or will they all be placed via the MSaaS model?
A:A part of the 100 leads will be CapEx sales.
Q:How many states in the United States are you now approved in for users to operate a system?
A:Currently approved in 8 states.
Q:Could you talk about the current revenue model? Is it mostly subscriptions versus CapEx in licensing?
A:The leading model is the MSaaS model, but there are also CapEx sales. In Europe, sales are primarily CapEx to distributors, while in the U.S., it is a mixture of CapEx and MSaaS models. Other territories depend on geographic traits.
Q:Could you give us a sense of where the AI solutions revenue should go going forward?
A:AI solutions revenue is expected to grow continuously, with 2026 being the breakeven year for revenues and expenses. Revenue recognition policies and agreements like Ezra Medical are contributing to growth.
Q:Any trends we should expect in operating expenses? When would you expect to start seeing the quarterly losses start to decline?
A:Operating expenses have been consistent at $11 million to $12 million per quarter. Efforts are being made to maintain this level while increasing sales and marketing expenses. Quarterly losses are expected to decline as revenue increases, especially in the second half of this year and beyond.
Q:Could you talk about studies, submittals, publications, and presentations in the back half of the year, specifically around RSNA?
A:The company will present the full Nanox end-to-end solution at RSNA, including the ARC X system and its first AI interpretation. A clinical paper on MSK has been submitted, and presentations will be made by the Chief Medical Officer and key opinion leaders.
Q:Could you talk about geographies for ARC placements and AI solutions for the balance of this year and through 2026-2027?
A:The focus is on the U.S. for both ARC and AI solutions, followed by Europe (8 countries, including Romania and Greece), and Latin America (e.g., Mexico). Efforts in the Far East and Africa are limited for now. AI pilots are ongoing in India and Thailand, and systems are installed in Israel.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact number of systems operating out of the 60 or 100 leads, instead giving a general figure of 'more than 20.' Additionally, while discussing AI solutions revenue, the response included vague language about growth and revenue recognition policies without specific projections for the near term.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI provider
ARC Nanox
ARC configuration
ARC deployment
ARC system
CTIS
Center
Dr
Duke
Fabrinet
Keiser University
Nanox AI
Nanox ARC
Nanox imaging
Radiology
Research Division
cancer
chain
collaboration Nanox
collaborator
deepc
footprint
front
health care
image
imaging technology
increase salary
lung
manufacturing service
opinion leader
paper
potential
production
publication
quality
screening
study
testing
tool
training
NNOX Transcript
Nano-X Imaging Ltd. (NNOX) Q1 2026 Earnings Call Transcript
Neutral6-25
Nano-X Imaging Ltd. (NNOX) Q4 2025 Earnings Call Transcript
Unknown4-20
The earnings call reveals mixed signals: a 23% revenue increase is positive, but widening losses and weak margins are concerning. The optimistic guidance for 2026 and strategic acquisition of Nanox Health IT Inc. provide potential upside. However, the lack of clear guidance on teleradiology growth and increased expenses, particularly in sales and marketing, offset these positives. The Q&A highlights management's reluctance to provide detailed forecasts, adding uncertainty. With no significant catalysts or market cap details, the stock is likely to remain neutral, fluctuating between -2% and 2% over the next two weeks.
Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
Nano-X Imaging Ltd. (NNOX) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: slight revenue growth and strategic market expansion are positive, but increased losses and vague management responses in the Q&A section are concerning. The company's focus on AI and regulatory achievements offer long-term potential, but short-term financial metrics and execution risks temper optimism. With no clear guidance improvement, the stock is likely to remain stable in the near term.
NNOX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
